Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021271 | 0.92 | NTRK1 (0.46) | NTRK1STAT6CCNT1CDK9ADORA2B | |
| SCHEMBL19010321 | 0.83 | NTRK1 (0.59) | NTRK1STAT6KDM4EMAPT | |
| SCHEMBL19010314 | 0.79 | STAT6 (0.52) | NTRK1STAT6CCNT1CDK9SRC | |
| SCHEMBL19010269 | 0.79 | STAT6 (0.57) | NTRK1STAT6CCNT1CDK9SRC | |
| SCHEMBL19010295 | 0.78 | KCNH2 (0.45) | NTRK1STAT6 | |
| SCHEMBL19010304 | 0.78 | STAT6 (0.46) | NTRK1STAT6CCNT1CDK9SRC | |
| SCHEMBL19010316 | 0.77 | GRM5 (0.48) | NTRK1ADORA2BKDM4E | |
| SCHEMBL19010302 | 0.76 | MAPK10 (0.47) | NTRK1STAT6CCNT1CDK9KDM4E | |
| SCHEMBL19010311 | 0.76 | NTRK1 (0.51) | NTRK1ADORA2BNTRK3NTRK2 | |
| SCHEMBL17021272 | 0.75 | NTRK1 (0.59) | NTRK1STAT6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | NTRK1 1410/4885STAT6 8/4885CCNT1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.